Yiqi Formula enhance inhibiting effect of cisplatin on triple⁃negative breast cancer by down regulating lncRNA HCP5

Jingjing WU; Tian MENG; Lina MA; Yue ZHOU; Yulian YIN; Hongfeng CHEN; hao CHEN

doi:10.16306/j.1008-861x.2022.03.007

您当前的位置：

首页 >

文章列表页 >

Yiqi Formula enhance inhibiting effect of cisplatin on triple⁃negative breast cancer by down regulating lncRNA HCP5

Experiment Research | 更新时间：2022-08-29

- Yiqi Formula enhance inhibiting effect of cisplatin on triple⁃negative breast cancer by down regulating lncRNA HCP5
- Academic Journal of Shanghai University of Traditional Chinese Medicine Vol. 36, Issue 3, Pages: 37-44(2022)
- 作者机构：
  
  1.上海中医药大学附属龙华医院中医乳腺科（上海　200032）
- 作者简介：
- 基金信息：
- DOI：10.16306/j.1008-861x.2022.03.007
  CLC：
扫描看全文
吴晶晶,孟畑,马丽娜等.益气小复方通过下调lncRNA HCP5增强顺铂对三阴性乳腺癌的抑制作用[J].上海中医药大学学报,2022,36(03):37-44.

WU Jingjing,MENG Tian,MA Lina,et al.Yiqi Formula enhance inhibiting effect of cisplatin on triple⁃negative breast cancer by down regulating lncRNA HCP5[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2022,36(03):37-44.
吴晶晶,孟畑,马丽娜等.益气小复方通过下调lncRNA HCP5增强顺铂对三阴性乳腺癌的抑制作用[J].上海中医药大学学报,2022,36(03):37-44. DOI： 10.16306/j.1008-861x.2022.03.007.

WU Jingjing,MENG Tian,MA Lina,et al.Yiqi Formula enhance inhibiting effect of cisplatin on triple⁃negative breast cancer by down regulating lncRNA HCP5[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2022,36(03):37-44. DOI： 10.16306/j.1008-861x.2022.03.007.

摘要

目的,2,探讨益气小复方增强顺铂对三阴性乳腺癌抑制作用的机制。,方法,2,①利用TCGA数据库，比较长链非编码RNA（lncRNA）HCP5在乳腺癌、三阴性乳腺癌肿瘤及瘤旁组织中的表达水平；②检测lncRNA HCP5，PTEN、p-Akt蛋白在三阴性乳腺癌肿瘤、瘤旁及非三阴性乳腺癌肿瘤组织中的表达水平；③构建三阴性乳腺癌裸鼠移植瘤模型，予以顺铂、益气小复方+顺铂干预，检测肿瘤体积、质量以及瘤体lncRNA HCP5，PTEN、p-Akt蛋白表达水平。,结果,2,①TCGA数据库中，lncRNA HCP5在乳腺癌肿瘤组织中的表达水平高于瘤旁组织，但差异无统计学意义（,P,>,0.05）；Basal-like亚型乳腺癌肿瘤组织中lncRNA HCP5表达水平高于瘤旁组织，差异有统计学意义（,P,<,0.01）。②三阴性乳腺癌肿瘤组织中lncRNA HCP5表达水平高于瘤旁及非三阴性乳腺癌组织（,P,<,0.01），PTEN蛋白表达水平低于瘤旁及非三阴性乳腺癌组织（,P,<,0.001），p-Akt蛋白表达水平高于瘤旁及非三阴性乳腺癌组织（,P,<,0.001）；③与顺铂组相比，益气小复方+顺铂组裸鼠移植瘤体积明显较小、质量较轻（,P,<,0.001），瘤体lncRNA HCP5和p-Akt蛋白表达水平降低（,P,<,0.001），PTEN蛋白表达水平升高（,P,<,0.001）。,结论,2,益气小复方可能通过下调lncRNA HCP5的表达来上调PTEN和下调p-Akt蛋白的表达，从而增强顺铂对三阴性乳腺癌的抑制作用。

Abstract

Objective： ,To explore the mechanism of Yiqi Formula enhancing the inhibiting function of cisplatin on triple-negative breast cancer.,Methods,2,①The expression levels of lncRNA HCP5 in breast cancer tumor tissues， triple-negative breast cancer tumor and tumor adjacent tissues were compared using TCGA database. ②The expression levels of lncRNA HCP5， PTEN and p-Akt protein in triple-negative breast cancer tumor and tumor adjacent tissues and non-triple-negative breast cancer tumor tissues were detected. ③The xenograft model of nude mice with triple-negative breast cancer was established and treated with cisplatin， Yiqi Formula + cisplatin. Tumor volume， weight and expression levels of lncRNA HCP5， PTEN and P-Akt protein in the tumor were measured.,Results,2,①The data of TCGA showed that the expression level of lncRNA HCP5 in breast cancer tumor tissues was higher than that in tumor adjacent tissues， but the difference was not statistically significant （,P,>,0.05）. In Basal-like breast cancer， the expression level of lncRNA HCP5 in tumor tissues was significantly higher than that in tumor adjacent tissues （,P,<,0.01）. ②In triple⁃negative breast cancer tumor tissues， the expression level of lncRNA HCP5 was higher than that in tumor adjacent tissues and non-triple-negative breast cancer tumor tissues （,P,<,0.01）, the expression level of PTEN protein was lower than that in tumor adjacent tissues and non-triple-negative breast cancer tumor tissues （,P,<,0.001）， and the expression level of p-Akt protein was higher than that in tumor adjacent tissues and non-triple-negative breast cancer tumor tissues （,P,<,0.001）.③Compared with cisplatin group， the tumor volume and weight of Yiqi Formula + cisplatin group was significantly smaller and lighter （,P,<,0.001）， the expression level of lncRNA HCP5 and p-Akt protein decreased（,P,<,0.001）， the expression level of PTEN protein increased（,P,<,0.001）.,Conclusion,2,Yiqi Formula may increase PTEN protein expression and decrease p-Akt protein expression by down regulating lncRNA HCP5， so as to enhance inhibiting effect of cisplatin on triple-negative breast cancer.

关键词

益气小复方顺铂三阴性乳腺癌lncRNA HCP5PTEN/p-Akt

Keywords

Yiqi Formulacisplatintriple-negative breast cancerlncRNA HCP5PTEN/p-Akt

references

BIANCHINI G，BALKO J M，MAYER I A，et al. Triple-negative breast cancer：challenges and opportunities of a heterogeneous disease［J］. Nat Rev Clin Oncol， 2016， 13（11）： 674-690.

陈俊青，陈占红，王晓稼. 2018年美国ASCO会议三阴性乳腺癌研究进展［J］. 实用肿瘤杂志，2018， 33（6）： 510-514.

胡升芳，谷焕鹏，陈红风，等. 陆德铭教授扶正袪邪法治疗乳腺癌经验［J］. 中华中医药学刊，2013， 31（12）： 2732-2734.

吴晶晶，马丽娜，代秋颖，等. 益气扶正法治疗三阴性乳腺癌回顾性研究［J］. 河北中医，2021， 43（1）： 61-63.

张玉柱，陈红风. 基于NF-κB 通路评价益气小复方对三阴性乳腺癌顺铂耐药的逆转作用［J］. 上海中医药大学学报，2018， 32（1）： 49-54.

王冰，张玉柱，陈红风. 益气小复方抑制三阴性乳腺癌外泌体传递耐药信息的作用机制研究［J］. 上海中医药大学学报，2018， 32（1）： 50-54.

MALIH S， SAIDIJAM M， MALIH N. A brief review on long noncoding RNAs： a new paradigm in breast cancer pathogenesis，diagnosis and therapy［J］. Tumour Biol， 2016， 37（2）： 1479-1485.

ZHANG Y， WU J， YE M， et al. ETS1 is associated with cisplatin resistance through IKKα/NF-κB pathway in cell line MDA-MB-231［J］. Cancer Cell Int， 2018， 18： 86.

ROBSON M E， TUNG N， CONTE P， et al. Olympi AD final overall survival and tolerability results： olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER-2 negative metastatic breast cancer［J］. Ann Oncol， 2019， 30（4）： 558-566.

JOVANOVIC B， MAYER I A， MAYER E L， et al. A randomized phase Ⅱ neoadjuvant study of cisplatin， paclitaxel with or without everolimus in patients with stage Ⅱ/Ⅲ triple-negative breast cancer （TNBC）： responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations， TNBC subtype， AR status， and Ki67［J］. Clin Cancer Res， 2017， 23（15）： 4035-4045.

TRAINA T A， MILLER K， YARDLEY D A， et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer［J］. J Clin Oncol， 2018， 36（9）： 884-890.

VIKAS P， BORCHERDING N， ZHANG W Z. The clinical promise of immunotherapy in triple-negative breast cancer［J］. Cancer Manag Res， 2018， 10： 6823-6833.

MEYER F， BECKER S， CLASSEN S， et al. Prevention of DNA replication stress by CHK1 leads to chemoresistance despite a DNA repair defect in homologous recombination in breast cancer［J］. Cells，2020，9（1）：238.

PANDY J，BALOLONG-GARCIA J C，CRUZ-ORDINARIO M，et al. Triple negative breast cancer and platinum-based systemic treatment： a meta-analysis and systematic review［J］. BMC Cancer，2019，19（1）：1065.

GRADISHAR W J， ANDERSON B O， ABRAHAM J， et al. Breast Cancer， Version 3.2020， NCCN Clinical Practice Guidelines in Oncology［J］. J Natl Compr Canc Netw，2020，18（4）：452-478.

HU X C，ZHANG J，XU B H，et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer （CBCSG006）：a randomised， open-label，multicentre，phase 3 trial［J］. LancetOncol， 2015， 16（4）： 436-446.

ZHANG J， FAN M，XIE J， et al. Chemotherapy of metastatic triple negative breast cancer： Experienceofusingplatinum-basedchemotherapy［J］. Oncotarget， 2015， 6（40）： 43135-43143.

TANG T， CHENG Y， SHE Q， et al. Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer［J］. Biomed Pharmacother， 2018， 107： 338-346.

SHIN V Y， CHEN J， CHEUK I W， et al. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness［J］. Cell Death Dis， 2019， 10（4）： 270.

WANG L， LUAN T， ZHOU S， et al. LncRNA HCP5 promotes triple negative breast cancer progression as a ceRNA to regulate BIRC3 by sponging miR-219a-5p［J］. Cancer Med， 2019， 8（9）： 4389-4403.

WU J， CHEN H， YE M， et al. Long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression［J］. Biomed Pharmacother， 2019， 115： 108869.

邓樱，陈红风. 黄芪注射液及其有效成分对乳腺癌细胞增殖和Akt磷酸化的影响［J］. 中西医结合学报，2009， 7（12）： 1174-1180.

叶媚娜，陈红风，周瑞娟，等. 黄芪多糖对基底细胞样乳腺癌细胞增殖和Akt磷酸化的影响［J］. 中西医结合学报，2011， 9（12）： 1339-1345.

LIAO M J， YE M N， ZHOU R J， et al. Yiqi formula enhances the antitumor effects of erlotinib for treatment of triple-negative breast cancer xenografts［J］. Evid Based Complement Alternat Med， 2014， 2014： 628712.

Views

194

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Evaluation of reversing effects of Yiqi Formula on cisplatin resistance in triple negative breast cancer based on NF-κB signaling pathway

Exploration on characteristics and research progress of traditional Chinese medicine in treatment of triple⁃negative breast cancer based on tumor⁃associated macrophages

Effects of dihydroartemisinin on proliferation and apoptosis of human triple-negative breast cancer MDA-MB-231 cells based on PI3K/AKT signaling pathway

Evaluation on drug-induced deficiency syndrome model by short-term administration of cisplatin in mice

Related Author

No data

Related Institution

Breast Department of Chinese Medicine,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Longhua Hospital， Shanghai University of Traditional Chinese Medicine

Shanghai University of Traditional Chinese Medicine

School of Basic Medical Sciences, Shanghai University of Traditional Chinese Medicine

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

⁰